Loading stock data…
Cognition Therapeutics (CGTX)
$1.09-0.03 (-2.68%)
Market ClosedLast close Jun 29
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cognition Therapeutics, Inc. in the Healthcare sector is trading at $1.09 with a market capitalization of $108M. Wall Street consensus targets $3.50 (4 analysts), implying a +221.1% move over the next 12 months. The stock is currently 72% below its 52-week high of $3.83, remaining 18.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +221.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.84M↓ | -$3.67M↑ | -$5.16M↑ | -$6.87M↑ | -$8.69M |
| Net Income | -$4.57M↓ | -$3.34M↑ | -$4.93M↑ | -$6.73M↑ | -$8.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$108.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.45%
Volume
Today's trading volume
1.81M
Recent News
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%
The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)
Cognition Therapeutics (NASDAQ:CGTX) shares gained 5% after the company announced that it had received written feedback from the U. S.
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Cognition Therapeutics, Inc. (NASDAQ:CGTX) is one of the most popular penny stocks on Robinhood. TheFly reported on May 21 that CGTX held a planned regulatory meeting with the U.S. Food and Drug Administration to review Phase 2 results […]
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit from an infected person and incidents are becoming more common on cruises, making a global […]
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diwan, PhD, will offer one-on-one meetings on the same day from 9:45AM to 2:45PM ET. […]